Gastrointestinal Diseases Market is expected to grow from USD 17.27 billion in 2016 and reach USD 19.79 billion in 2022, growing at a CAGR of 2.3% during the forecast period. Due to this primary growth factor, the global gastro paresis drugs market will increase USD 940 million between 2016-2022, exceeding USD 7.1 billion in market size by the end of the forecast period. This growth in market size is attributed to numerous factors including increasing consumption of biologics, tentative approval of late stage molecules, development of novel therapies using innovative technologies, and improved diagnostic tools increasing the treatment-seeking population. Our industry experts anticipate that within the gastrointestinal diseases market, the GIT Anti-inflammatory drug will grow at the fastest CAGR ranging from 1% to .5%, during the forecast period. Based on the geographic regions, our experts anticipate that Europe will be the fastest-growing segment during the forecast period. The Europe region will grow at a CAGR ranging from 1% to 0.3% by 2022.